After deal value peaked in 2021 and then plummeted in the wake of the pandemic, dealmaking in the life sciences sector revived in 2023. Acquiring pre-commercial biotech assets to fuel growth renewed deal success for pharmaceutical companies, and proactively shaping the business portfolio to improve profitability provided the key for medical technology companies. This year promises considerable deal activity across the sector.
Read the full article: Life Sciences M&A Shows New Signs of Life //
Source: https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-m-and-a-shows-new-signs-of-life